Evidence map›Paper›PMID 34202446›Full record

ArticleMolecules (Basel, Switzerland)2021

Antimicrobial Peptide Dendrimers and Quorum-Sensing Inhibitors in Formulating Next-Generation Anti-Infection Cell Therapy Dressings for Burns.

Paris Jafari, Alexandre Luscher, Thissa Siriwardena, Murielle Michetti, Yok-Ai Que, Laurence G Rahme, Jean-Louis Reymond, Wassim Raffoul, Christian Van Delden, Lee Ann Applegate and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
  3. In Silico and In vitro Evaluations of the Antibacterial Activities of HIV-1 Nef Peptides againstInternational journal of molecular and cellular medicine · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Paris JafariRegenerative Therapy Unit (UTR), Department of Musculoskeletal Medicine DAL, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Alexandre LuscherDepartment of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva, Switzerland.
Thissa SiriwardenaDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, 3012 Bern, Switzerland.
Murielle MichettiRegenerative Therapy Unit (UTR), Department of Musculoskeletal Medicine DAL, Lausanne University Hospital, 1011 Lausanne, Switzerland.
Yok-Ai QueDepartment of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Laurence G RahmeDepartment of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA.
Jean-Louis ReymondDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0003-2724-2942
Wassim RaffoulService of Plastic, Reconstructive & Hand Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland.ORCID 0000-0002-3524-0077
Christian Van DeldenDepartment of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva, Switzerland.
Lee Ann ApplegateRegenerative Therapy Unit (UTR), Department of Musculoskeletal Medicine DAL, Lausanne University Hospital, 1011 Lausanne, Switzerland.ORCID 0000-0002-7346-9921
Thilo KöhlerDepartment of Microbiology and Molecular Medicine, University of Geneva, 1211 Geneva, Switzerland.
University of Bern · CHUniversity of Geneva · CHUniversity of Lausanne · CHHarvard University · USUniversity of Utah · USUniversity of Zurich · CH

Funding

Interruption of Signaling-Mediated Bacterial Persistent InfectionsR33AI105902 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAHME, LAURENCE G · 2015 to 2017
$1.8M
Interruption of Signaling-Mediated Bacterial Persistent InfectionsR21AI105902 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAHME, LAURENCE G · 2013 to 2014
$478k
NIAID NIH HHS R21 AI105902NIAID NIH HHS R33 AI105902Swiss National Science Foundation 200020_159941
6 · The paper itself

Abstract

Multidrug resistance infections are the main cause of failure in the pro-regenerative cell-mediated therapy of burn wounds. The collagen-based matrices for delivery of cells could be potential substrates to support bacterial growth and subsequent lysis of the collagen leading to a cell therapy loss. In this article, we report the development of a new generation of cell therapy formulations with the capacity to resist infections through the bactericidal effect of antimicrobial peptide dendrimers and the anti-virulence effect of anti-quorum sensing MvfR (PqsR) system compounds, which are incorporated into their formulation. Anti-quorum sensing compounds limit the pathogenicity and antibiotic tolerance of pathogenic bacteria involved in the burn wound infections, by inhibiting their virulence pathways. For the first time, we report a biological cell therapy dressing incorporating live progenitor cells, antimicrobial peptide dendrimers, and anti-MvfR compounds, which exhibit bactericidal and anti-virulence properties without compromising the viability of the progenitor cells.

Indexed as

Anti-Bacterial AgentsBurnsCell- and Tissue-Based TherapyDendrimersPore Forming Cytotoxic ProteinsCells, CulturedHumansPseudomonas aeruginosaPseudomonas InfectionsQuorum SensingAnti-Bacterial AgentsDendrimersPore Forming Cytotoxic Proteinsanti-infection dressingantimicrobial peptide dendrimersbiological bandageburn woundcell therapyMvfRPqsRquorum-sensing inhibitors

Identifiers

PMID34202446
PMCPMC8270311
OpenAlexW3174637979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.